Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), along with Clinilabs Drug Development Corporation, has been granted a Schedule I license from the U.S. Drug Enforcement Agency (“DEA”) to support the first-in-human phase 1/2a clinical trial of its proprietary CYB003. The DEA license required in order for a company to study, produce, analyze or otherwise work with Schedule I controlled substances. Cybin is partnering with Clinilabs, a global, full-service contract research organization with deep expertise in central nervous system drug development, to develop CYB003, a proprietary deuterated psilocybin analog that is being evaluated for the treatment of major depressive disorder (“MDD”). CYB003 has the potential to overcome the challenges and limitations of oral psilocybin and, in tests, has achieved less variability in plasma levels, faster onset of action and shorter duration of effect. The company believes that CYB003 may reduce time and resource burden on patients, providers, and payers, and possibly improve scalability and accessibility of treatment. “Obtaining a DEA license for our phase 1/2a trial is the final step clearing the way to begin dosing participants in our first-in-human study of CYB003,” said Cybin CEO Doug Drysdale in the press release. “Our rigorous recruitment and enrollment process is well under way, and we are excited to commence dosing of our first cohort of participants.”
To view the full press release, visit https://ibn.fm/ccnOk
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
